If you’ve been researching weight loss medications, you’ve probably come across both Mounjaro vs. Zepbound and wondered: are they really the same thing? The short answer is yes — and no. Both drugs contain the exact same active ingredient, tirzepatide. But they are FDA-approved for very different reasons. Understanding that difference can save you thousands of dollars and help you get the right prescription. Let’s break it all down in simple terms.
What Is Tirzepatide?
Tirzepatide is the active ingredient in both Mounjaro and Zepbound. It belongs to a class of medications called GLP-1 and GIP receptor agonists.
Tirzepatide is the active ingredient in both Mounjaro and Zepbound. It belongs to a class of medications called GLP-1 and GIP receptor agonists.
Here’s how it works in plain English:
- It mimics two natural gut hormones — GLP-1 and GIP.
- These hormones tell your brain you’re full.
- They also slow down digestion.
- They help your body release insulin after meals.
- The result: less hunger, better blood sugar control, and weight loss.
This dual-hormone action is what makes tirzepatide more powerful than older weight loss drugs that only target one hormone.
What Is Mounjaro?
Mounjaro is the brand name for tirzepatide that was FDA-approved in May 2022 to treat type 2 diabetes in adults.
It is used alongside diet and exercise to:
- Lower blood sugar (A1C) levels.
- Improve insulin response.
- Reduce post-meal blood sugar spikes.
Key fact: Mounjaro is not officially approved for weight loss. However, because tirzepatide causes significant weight reduction as a side effect, many doctors prescribe it off-label for weight management.
Clinical trials (SURPASS program) showed Mounjaro helped people with type 2 diabetes lose 15–20 pounds on average — a powerful secondary benefit.
What Is Zepbound?
Zepbound is the brand name for tirzepatide that was FDA-approved in November 2023 specifically for chronic weight management.
Zepbound is approved for adults who:
- Have a BMI of 30 or higher (obesity).
- Have a BMI of 27 or higher with at least one weight-related condition (such as high blood pressure, high cholesterol, or type 2 diabetes).
In December 2024, the FDA also approved Zepbound for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity — making it the first-ever medication approved for that condition.
Clinical trials (SURMOUNT-1) showed Zepbound users lost an average of 20.9% of their body weight at the highest dose (15 mg) over 72 weeks. For a 250-pound person, that’s roughly 52 pounds.
Mounjaro vs. Zepbound: Side-by-Side Comparison
| Feature | Mounjaro | Zepbound |
| Active Ingredient | Tirzepatide | Tirzepatide |
| Manufacturer | Eli Lilly | Eli Lilly |
| FDA Approval | Type 2 Diabetes (2022) | Weight Loss & Sleep Apnea (2023/2024) |
| Dosing Schedule | Once weekly | Once weekly |
| Available Doses | 2.5 mg to 15 mg | 2.5 mg to 15 mg |
| Injection Type | Single-use pen | Single-use pen, vials, KwikPen |
| List Price (Monthly) | ~$1,080 | ~$1,086 |
| Insurance Coverage | Easier for diabetics | Harder to get approved |
Are They the Same Drug?
Molecularly — yes. Legally — no.
Mounjaro and Zepbound contain identical tirzepatide molecules. The body cannot tell them apart. They work the same way.
But they have different FDA labels, different insurance coverage rules, and different brand names. Eli Lilly created two separate products on purpose. One targets the diabetes market. The other targets the obesity market. The difference is all about approvals and insurance — not the drug itself.
Important: You should never take both at the same time. There is no benefit, and it increases the risk of serious side effects.
Which One Is Right for You?
The right choice depends on your medical situation:
Choose Mounjaro if you:
- Have a type 2 diabetes diagnosis.
- Want better insurance coverage for your medication.
- Need to improve your A1C levels and blood sugar control.
Choose Zepbound if you:
- Are focused primarily on weight loss.
- Have obesity or are overweight with a related health condition.
- Have moderate-to-severe obstructive sleep apnea.
Your doctor will guide this decision based on your full medical history. Do not try to switch between the two without consulting a healthcare provider.
What About Side Effects?
Both medications carry the same side effect profile since they are the same drug.
Common side effects include:
- Nausea (most common, especially at first)
- Diarrhea
- Constipation
- Vomiting
- Stomach pain
Most side effects are mild and improve after the first few weeks. Doctors recommend starting at the lowest dose (2.5 mg) and gradually increasing every four weeks to reduce discomfort.
Serious (but rare) side effects include:
- Pancreatitis (inflammation of the pancreas).
- Gallbladder problems.
- Low blood sugar (especially if combined with insulin).
- Thyroid tumors (Black Box Warning — do not use if you have a personal or family history of medullary thyroid carcinoma).
What Does It Cost?
Without insurance, both medications cost approximately $1,080–$1,086 per month at list price.
With insurance:
- Mounjaro may be covered for diabetic patients, copays can drop to as low as $25/month with the Eli Lilly savings card.
- Zepbound coverage is harder to get. Many insurers consider obesity drugs “lifestyle medications” and exclude them.
Without insurance:
- Eli Lilly’s savings card for Zepbound can reduce the price to roughly $550/month for commercially insured patients.
- A newer LillyDirect Self-Pay program offers Zepbound vials starting at $299/month.
Real patient experience: Jessica, a 38-year-old from Texas, was prescribed Zepbound, but her insurance denied coverage. After appealing and working with her doctor to document medical necessity, coverage was approved on the second attempt. Her advice: “Don’t give up after the first denial. Get your doctor to write a letter of medical necessity.”
A More Accessible Option for Weight Loss
If you’re struggling with high brand-name costs or insurance hurdles, telehealth programs can offer a more flexible path.
TirzepatideRX provides a physician-supervised weight loss program built around once-weekly tirzepatide injections. Everything is handled online — from your initial consultation to medication delivery right to your door.
Their program includes three pricing plans:
- Monthly Plan – $399/month: Weekly injections, progress monitoring, and the flexibility to cancel anytime
- 3-Month Plan – $1,125 total: Full medication supply for 90 days, quarterly health assessments, and priority support
- 6-Month Plan – $2,199 total: Maximum savings, bi-monthly check-ins, premium support, and personalized nutritional guidance
Ready to get started? Begin your weight loss journey here with a quick online consultation.
Does Insurance Cover These Medications?
This is one of the biggest questions people have when comparing Mounjaro vs. Zepbound.
Here’s the simple breakdown:
- Mounjaro: Most commercial insurance plans cover it for type 2 diabetes. Prior authorization is usually required.
- Zepbound: Harder to get covered. Many plans exclude weight loss drugs entirely. However, coverage is expanding. In 2025, about 16–43% of employers covered GLP-1 drugs for weight loss.
- Medicare: May cover Mounjaro for diabetes. As of late 2025, Eli Lilly and the U.S. government reached an agreement to expand Zepbound access to Medicare beneficiaries with obesity at as low as $50/month.
- Medicaid: Varies by state. Some states cover GLP-1s for weight loss; many do not.
Pro tip: Before your doctor’s appointment, log into your insurance portal and search your drug formulary (the list of covered medications) for both brand names.
The Bottom Line
When it comes to Mounjaro vs. Zepbound, the real difference comes down to one thing: what condition your doctor is treating. Same drug. Same doses. Same side effects. But different FDA labels, different insurance rules, and different access pathways.
If you have type 2 diabetes, Mounjaro is typically the better-covered option. If your primary goal is weight loss, Zepbound — or a supervised tirzepatide telehealth program — may be the smarter path.
Want to explore more articles on tirzepatide, weight loss medications, and healthy living? Visit the TirzepatideRX blog for expert-written guides updated regularly.
Frequently Asked Questions (FAQ)
Is Mounjaro the same as Zepbound?
Yes, both contain tirzepatide, but they have different FDA approvals — Mounjaro for diabetes and Zepbound for weight loss.
Can I use Mounjaro for weight loss?
It can be prescribed off-label for weight loss, but insurance coverage is unlikely without a diabetes diagnosis.
Which drug causes more weight loss — Mounjaro or Zepbound?
Clinical trials show Zepbound users lose slightly more weight (up to 20.9%) since its dosing was optimized specifically for weight management.
Can I take Mounjaro and Zepbound together?
No, they contain the same ingredient, so taking both offers no added benefit and increases the risk of side effects.
Does Zepbound help with sleep apnea?
Yes, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in December 2024.
How long does it take to see results?
Most people notice appetite suppression within 2–4 weeks, with significant weight loss beginning around weeks 8–12.
What if my insurance denies coverage?
You can appeal the decision, and your doctor can submit a letter of medical necessity. Over 80% of prior authorization appeals succeed when properly documented.
Sources
- FDA – Mounjaro (Tirzepatide) Prescribing Information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
- FDA – Zepbound (Tirzepatide) Prescribing Information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
- FDA – Approval of Zepbound for Obstructive Sleep Apnea: https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
- SURMOUNT-1 Clinical Trial (NEJM): https://pubmed.ncbi.nlm.nih.gov/35658024/
- SURPASS Clinical Trial – Tirzepatide vs. Semaglutide (NEJM): https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
- StatPearls – Tirzepatide Overview (NCBI): https://www.ncbi.nlm.nih.gov/books/NBK585056/
- Eli Lilly – Zepbound Savings & Coverage: https://zepbound.lilly.com/coverage-savings
- Eli Lilly – U.S. Government Agreement to Expand Access: https://lilly.gcs-web.com/news-releases/news-release-details/lilly-and-us-government-agree-expand-access-obesity-medicines
- CMS – Medicare Coverage Changes 2026: https://www.cms.gov/newsroom/fact-sheets/contract-year-2026-policy-and-technical-changes-medicare-advantage-program-medicare-prescription
